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T helper 17 (Th17) cells play an important role in
mucosal host defense through production of the
signature cytokines IL-17 and IL-22. Prostaglandin
E2 (PGE2) has been shown to enhance IL-17 produc-
tion by mature Th17 cells. However, when present
during Th17 cell differentiation, we found that PGE2
inhibited the transcription factor IRF4 and sup-
pressed production of IL-17 but not IL-22. We show
that IRF4 was required for IL-17 expression but in-
hibited IL-22 expression, highlighting the potential
for discordant regulation of these two cytokines in
Th17 cells. The pathogenic fungus Cryptococcus
neoformans produces PGE2, and we found that it
uses PGE2- and IRF4-dependent mechanisms to
specifically inhibit induction of IL-17 during Th17
cell differentiation. Blockade of host PGE2 during
infection led to increased IL-17 production from
CD4+ T cells and increased survival of mice. These
findings suggest that host- or pathogen-derived
PGE2 can act directly on Th17 cells during differen-
tiation to inhibit IL-17-dependent antimicrobial
responses.
INTRODUCTION
T helper 17 (Th17) cells play an important role in mucosal host
defense. Through production of the signature cytokines IL-17
and IL-22, Th17 cells trigger antimicrobial responses such as
neutrophil recruitment and antimicrobial peptide secretion
(Ouyang et al., 2008). IL-17 plays an important role in responses
against pathogenic fungi such asCandida albicans. Mice lacking
IL-17 develop more severe oral and skin candidiasis compared
to wild-type mice (Conti et al., 2009; Kagami et al., 2010) and hu-
mans with impaired IL-17 signaling or IL-17 autoantibodies have
recurrent mucocutaneous candidiasis (Burbelo et al., 2010;
Kisand et al., 2010; Puel et al., 2010, 2011). In addition, IL-17
expression has been correlated with protection against the668 Immunity 36, 668–679, April 20, 2012 ª2012 Elsevier Inc.fungal opportunistic pathogens Cryptococcus neoformans and
Pneumocystis jiroveci (Kleinschek et al., 2006; Mu¨ller et al.,
2007; Rudner et al., 2007; Zhang et al., 2009).
Recent work has shown that prostaglandin E2 (PGE2) can
enhance IL-17 production from previously polarized Th17 cells
(Boniface et al., 2009; Chizzolini et al., 2008; Napolitani et al.,
2009; Yao et al., 2009). PGE2 can exert pro-inflammatory and
anti-inflammatory effects depending on the context and target
of its action. For example, PGE2 inhibits the proliferation of
T cells and suppresses IFN-g production from mature Th1 cells
(Betz and Fox, 1991; Harris et al., 2002; Hasler et al., 1983). In
contrast, a recent study found that PGE2 enhances IFN-g
production during the differentiation of Th1 cells from naive
T cells (Yao et al., 2009). These studies suggest that PGE2 differ-
entially affects T cell cytokine production depending on the
developmental state of the cell.
In mammals, PGE2 synthesis involves arachidonic acid
metabolism by cyclooxygenases (COX). Recognition of fungi
by the innate immune system can lead to host PGE2 production
(Gagliardi et al., 2010; Smeekens et al., 2010). Interestingly,
several pathogenic fungi, including Cryptococcus neoformans
and Candida albicans, have been reported to synthesize PGE2
from arachidonic acid by COX-independent enzymatic mecha-
nisms (Erb-Downward and Huffnagle, 2007; Erb-Downward
and Noverr, 2007). The virulence factor laccase has been identi-
fied as the enzyme required for PGE2 synthesis in Cryptococcus
neoformans (Erb-Downward et al., 2008; Zhu and Williamson,
2004).
Although recent work has shown that PGE2 enhances IL-17
production from memory Th17 cells in humans and mice, we
hypothesized that fungal- or host-derived PGE2 encountered
by naive T cells during early stages of infection may influence
the fate of these cells. In contrast to its ability to enhance
memory T cell IL-17 production, we found that PGE2 inhibited
the production of IL-17 from naive T cells exposed to Th17
cell differentiation conditions. Cryptococcus similarly inhibited
IL-17 production in a PGE2-dependent manner. We further
found that PGE2 inhibited DNA binding and expression of
the transcription factor IRF4, resulting in specific blockade of
IL-17 but not IL-22, another Th17 cell-associated cytokine. Inhi-
bition of PGE2 synthesis in vivo during cryptococcal infection
resulted in increased T cell IL-17 production and improved
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Figure 1. PGE2 Suppresses the Develop-
ment of Th17 Cells
(A) Intracellular IL-17 and IFN-g staining in naive
CD4+ T cells activated for 3 days in the presence
of TGF-b (1 ng/ml), IL-6, and PGE2 (top). Cells
initially activated with TGF-b and IL-6 were re-
stimulated for an additional 3 days in the presence
of PGE2, IL-23, or both (bottom).
(B) IL-17 protein expression (left) and relative IL-17
mRNA expression (right) after 3 days of stimula-
tion with 0.1, 1.0, or 10.0 mM of PGE2, the EP2
agonist butaprost, the EP4 agonist misoprostol, or
the EP1 and EP3 agonist sulprostone.
(C) IL-17 protein and mRNA expression after
3 days of stimulation under the indicated condi-
tions with PGE2 (1 mM) or forskolin (10 mM).
Data shown as mean ± SD. See also Figure S1.
Immunity
PGE2 Suppresses IRF4 and IL-17survival. These results show that host and cryptococcal PGE2
production can contribute to fungal virulence by directly inhibit-
ing the polarization of naive T cells into IL-17-secreting effector
cells.
RESULTS
PGE2 Suppresses IL-17 Production from Naive T Cells
Given that PGE2 has been shown to increase IL-17 production
from previously polarized Th17 cells, we explored whether
PGE2 could act on naive T cells and influence their differentiation
into Th17 cells. We differentiated naive CD4+ T cells under Th17
cell polarization conditions (anti-CD3+anti-CD28+IL-6+TGF-b)
for 3 days. Intracellular cytokine analysis revealed that the
addition of PGE2 at the beginning of polarization strikingly
reduced IL-17 production (Figure 1A, top). In contrast,
secondary stimulation of previously polarized Th17 cells for anImmunity 36, 668–6additional 3 days in combination with
PGE2, IL-23, or both enhanced IL-17
production (Figure 1A, bottom; Boniface
et al., 2009; Chizzolini et al., 2008; Napo-
litani et al., 2009; Yao et al., 2009).
Among the four mammalian PGE2
receptors, T cells express only EP2 and
EP4 (Figure S1 available online; Boniface
et al., 2009; Napolitani et al., 2009; Yao
et al., 2009). Consistent with this, the
EP2 agonist butaprost and the EP4
agonist misoprostol inhibited expression
of IL-17 transcript and protein, whereas
the EP1 and EP3 agonist sulprostone
had no effect (Figure 1B). PGE2 was
a more potent inhibitor of IL-17 than
either receptor agonist alone (Figure 1B),
suggesting a combinatorial effect of EP2
and EP4 signaling. Of note, EP2 and
EP4 both increase intracellular cAMP,
whereas EP1 and EP3 do not (Harris
et al., 2002). The ability of forskolin,
a cAMP-inducing agent, to mimic the
inhibitory effects of PGE2 on IL-17expression further supported the involvement of EP2 and EP4
(Figure 1C). Taken together, these results indicate that PGE2
can act via T cell EP2 and EP4 receptors to suppress induction
of IL-17 during T cell differentiation.
PGE2 Does Not Suppress IL-22 Induction
Titration of PGE2 revealed that the inhibitory effect on IL-17
expression is evident at concentrations of 10 nM and greater
(Figure 2A). In contrast, these concentrations of PGE2 caused
a slight increase in IL-22 production (Figure 2B). The inhibitory
effects of PGE2 selectively on IL-17 persisted even when IL-1b
and IL-23 were added during Th17 cell polarization (Figure 2C),
a condition that greatly enhanced production of IL-17 and
IL-22 in the absence of PGE2 (Chung et al., 2009; Datta et al.,
2010). These findings suggest that PGE2 targets a factor that
differentially regulates IL-17 and IL-22, two cytokines that are
often coordinately regulated in Th17 cells.79, April 20, 2012 ª2012 Elsevier Inc. 669
02000
4000
6000
8000
10000
0
200
400
600
800
0
50
100
150
200
0
5
10
15
R
el
at
iv
e 
ex
pr
es
si
on
PGE2   -     -   12  11  10    9    8   7    6    5
-n
TGF-β+IL-6(10  M) 
PGE2   -     -   12  11  10    9    8   7    6    5
-n
TGF-β+IL-6(10  M) 
IL-17
IL-22
R
el
at
iv
e 
ex
pr
es
si
on
IL-22
ng
/m
l
ng
/m
l
A
C
B
IL-17
       -             +         
TGF-β+IL-1β
+IL-23+IL-6
PGE2        -             +         
TGF-β+IL-1β
+IL-23+IL-6
PGE2
***
0.0
0.5
1.0
1.5
2.0
2.5
0
5
10
15
PGE2   -     -   12  11  10    9    8   7    6    5
-n
TGF-β+IL-6(10  M) 
PGE2   -     -   12  11  10    9    8   7    6    5
-n
TGF-β+IL-6(10  M) 
IL-17
IL-22
ng
/m
l
ng
/m
l
0
5
10
15
20
25
0
0.5
1.0
1.5
       -   +  +  +  +  +        -   +  +  +  +  +    
       -   -   -   -                
IL-6
TGF-β
- PGE2 + PGE2
ng
/m
l
ng
/m
l
0
20
40
60
80
100
0
1000
2000
3000
IL-17 IL-22
R
el
at
iv
e 
ex
pr
es
si
on
R
el
at
iv
e 
ex
pr
es
si
on
D
       -  +  +  +  +  +        -   +  +  +  +  +    
       -   -   -   -                
IL-6
TGF-β
- PGE2 + PGE2
Figure 2. PGE2 Suppresses IL-17, but Not IL-22,
Induction by TGF-b and IL-6
(A) IL-17 mRNA (left) and protein (right) 3 days after stim-
ulation of naive CD4+ T cells in the presence of TGF-b and
IL-6 with PGE2 titration.
(B) IL-22 mRNA (left) and protein (right) 3 days after stim-
ulation as in (A).
(C) Supernatant IL-17 and IL-22 from naive CD4+ T cells
activated for 3 days with TGF-b, IL-1b, IL-23, and IL-6 with
or without PGE2 (1 mM).
(D) IL-17 and IL-22 protein (top) and transcript (bottom)
after activation of naive CD4+ T cells for 3 days in the
presence of IL-6 and TGF-b (0.1, 1.0, 10, or 100 ng/ml) with
or without 1 mM PGE2.
Data shown as mean ± SD.
Immunity
PGE2 Suppresses IRF4 and IL-17PGE2 Effects on Th17 Cell Differentiation
Do Not Involve TGF-b
TGF-b is known to enhance IL-17 and suppress IL-22 (Rutz et al.,
2011). In light of the ability of both PGE2 and TGF-b to differen-
tially regulate these Th17 cell-associated cytokines, we exam-
ined whether PGE2 exerted its effects by interacting with the670 Immunity 36, 668–679, April 20, 2012 ª2012 Elsevier Inc.TGF-b pathway. PGE2 still inhibited the low
amounts of IL-17 produced by T cells differenti-
ated in the absence of TGF-b and inhibited IL-17
over a wide range of TGF-b concentrations (Fig-
ure 2D). Furthermore, PGE2 did not influence
the ability of TGF-b to suppress IL-22 (Fig-
ure 2D). These results suggest that PGE2 and
TGF-b exert their effects on Th17 cell differenti-
ation independently of each other.
PGE2 Suppresses Expression of IRF4 and
Rorgt
To identify the mechanism by which PGE2
suppresses IL-17 induction, we next focused
on the IL-6 signaling pathway central to Th17
cell differentiation. Signaling through the IL-6
receptor induces phosphorylation of STAT3,
which then translocates to the nucleus and
regulates many Th17 cell-associated genes.
Patients with Job’s (or hyper IgE) syndrome
carry STAT3 mutations that decrease IL-17
production from T cells and predispose to fungal
infections (Holland et al., 2007; Milner et al.,
2008). In mice, Stat3/ T cells are defective in
production of IL-17, IL-22, Rorgt, and IRF4,
consistent with the ability of STAT3 to bind
directly to regulatory regions of these genes
(Durant et al., 2010). PGE2 did not change the
phosphorylation status of STAT3 in response
to TGF-b and IL-6, making STAT3 an unlikely
target of PGE2 (Figures 3A, S2A, and S2B).
IRF4, another transcription factor required for
Th17 cell differentiation, is induced upon TCR
activation and further upregulated by TGF-
b and IL-6 (Bru¨stle et al., 2007; Chung et al.,
2009). PGE2 suppressed this upregulation of
IRF4 during Th17 cell differentiation (Figure 3B).IRF4 transcripts decreased as early as 24 hr after PGE2 treat-
ment (Figure 3C). PGE2 treatment also led to the downregulation
of IRF4 in memory Th17 cells (Figure S2C).
Downstream of STAT3 and IRF4, Rorgt is a transcriptional
activator that controls expression of both IL-17 and IL-22 (Ivanov
et al., 2006; Sanos et al., 2009; Trifari et al., 2009; Yang et al.,
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10 min 30 min Figure 3. PGE2 Alters Expression of Th17 Cell-
Associated Transcription Factors
(A) Unphosphorylated and phosphorylated STAT3
(pY705) detected by immunoblot at 10 and 30 min post-
activation with anti-CD3+anti-CD28 magnetic beads and
the cytokines indicated.
(B) Intracellular IRF4 detected by flow cytometry in naive
T cells after Th17 cell differentiation for 3 days in the
absence (shaded histogram) or presence (open histogram)
of PGE2.
(C) Relative IRF4 mRNA expression 24 and 48 hr after
stimulation under the indicated conditions with 0.1 and
1.0 mM PGE2.
(D–F) Relative mRNA expression of Rorgt (D), Rora (E),
and AHR (F) 3 days after activation with TGF-b and IL-6,
with or without PGE2. Results shown are relative to
activation (anti-CD3+anti-CD28) in the absence of TGF-b
and IL-6.
Data shown as mean ± SD. See also Figure S2.
Immunity
PGE2 Suppresses IRF4 and IL-172007). PGE2 suppressed the induction of Rorgt by TGF-b and
IL-6 (Figure 3D). Rora, which is also important for Th17 cell
development and is regulated similarly to Rorgt (Yang et al.,
2008), was also suppressed by PGE2 (Figure 3E), suggesting
that the target of PGE2 is upstream of both Rora and Rorgt.
PGE2 also downregulated AHR (Figure 3F), a transcription factor
important for IL-17 and IL-22 expression (Quintana et al., 2008;
Veldhoen et al., 2008). However, downregulation of AHR is
associated with decreased IL-22. Therefore, the increased
IL-22 seen with PGE2 was inconsistent with an AHR-mediated
effect.
Because PGE2 did not affect STAT3 phosphorylation
but affected Th17 cell-associated transcription factors down-
stream of STAT3, we investigated which of these effects could
account for the decreased IL-17 and increased IL-22 ex-
pression seen with PGE2. A dramatic reduction in IL-17,
IL-22, IRF4, and Rorgt in Stat3/ cells confirmed the central
role of STAT3 in Th17 cell differentiation (Figure S3A). STAT3
upregulates IL-17 expression by directly binding to the IL-17
promoter (Chen et al., 2006). Binding of STAT3 to the IL-22
promoter has not been demonstrated, but the decreased
IL-22 expression in Stat3/ cells may be explained by the
requirement of STAT3 for Rorgt production, important forImmunity 36both IL-17 and IL-22 expression (Ivanov et al.,
2006; Nurieva et al., 2007; Sanos et al., 2009;
Trifari et al., 2009; Yang et al., 2007). Indeed,
loss of Rorgt (Rorc/) resulted in decreased
relative expression of both IL-17 and IL-22
(Figure 4A). IL-17 transcript and protein ex-
pression were completely Rorgt dependent,
but low amounts of Rorgt-independent IL-22
were expressed under low TGF-b conditions
(Figure S3B). Taken together, these results
indicate that PGE2 modulates canonical
Th17 cell-inducing transcriptional pathways.
However, the coordinate regulation of IL-17
and IL-22 by AHR and Rorgt led us to hypoth-
esize that IRF4, whose role in IL-22 regulation
has been incompletely defined, may be acandidate mediator of the differential effect of PGE2 on these
two cytokines.
Loss of IRF4 Leads to Increased IL-22 Production
IRF4 expression was unaffected by Rorgt deficiency (Figure 4A),
suggesting that loss of IL-17 and IL-22 production in the absence
of Rorgt was not mediated by IRF4. Surprisingly, in the absence
of IRF4, IL-17 expression was suppressed and IL-22 was
increased (Figure 4B). siRNA gene targeting of IRF4 during
Th17 cell differentiation confirmed the decreased IL-17 and
increased IL-22 production (Figure 4C). When IL-23 and IL-1b
were included during Th17 cell differentiation, the absence of
IRF4 still led to decreased IL-17 and increased IL-22 expression
(Figure 4D). The effects of IRF4 deficiency were similar in the
absence of TGF-b, and increasing doses of TGF-b still inhibited
IL-22 in IRF4-deficient cells (Figure S3C). These data identify
that IRF4 is required for IL-17 expression but acts as an inhibitor
of IL-22 expression.
PGE2 Inhibits DNA Binding of IRF4
Unlike STAT3 and Rorgt deficiency, IRF4 deficiency mimicked
the ability of PGE2 to inhibit IL-17 expression and promote
IL-22 expression. Loss of IRF4 also reproduced the effect of, 668–679, April 20, 2012 ª2012 Elsevier Inc. 671
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Figure 4. IRF4 Deficiency Inhibits IL-17 Expression and Enhances
IL-22 Expression
(A and B) Relative mRNA expression of IL-17, IL-22, and IRF4 after Th17 cell
differentiation of naive CD4+ T cells from Rorc/ (A) and Irf4/ (B) mice (‘‘KO’’
in figure).
(C) siRNA gene targeting of IRF4 expression in naive T cells stimulated with
anti-CD3+anti-CD28+IL-6+TGF-b was confirmed by flow cytometry (left).
Shaded histogram shows cells transfected with a scrambled siRNA; open
histogram shows cells transfected with siRNA against IRF4. Supernatant IL-17
and IL-22 were detected after 3 days of stimulation (right).
(D) Supernatant IL-17 and IL-22 from wild-type or Irf4/ (‘‘KO’’ in figure)
naive CD4+ T cells activated in the presence of anti-CD3+anti-CD28, TGF-b
(1 ng/ml), IL-1b, IL-23, and IL-6 for 3 days.
Data shown as mean ± SD. See also Figure S3.
Immunity
PGE2 Suppresses IRF4 and IL-17PGE2 on expression of other genes (Figure 5A), further suggest-
ing that the effect of PGE2 on IL-17 and IL-22 may be mediated
by its suppression of IRF4. Polarization of IRF4-deficient naive
T cells confirmed that IRF4 was absolutely required for IL-17
induction (Figure 5B). The failure of PGE2 to augment IL-22 in
IRF4-deficient cells indicated that IRF4 mediated this effect.
Unexpectedly, the increased IL-22 expression seen with IRF4
deficiency was suppressed by PGE2 (Figure 5B), suggesting
not only that IRF4 was required for PGE2-mediated enhance-
ment of IL-22 expression but that an additional mechanism of
PGE2-mediated inhibition of IL-22was unmasked in the absence
of IRF4. Consistent with the induction of multiple pathways by
PGE2, retroviral overexpression of IRF4 failed to reverse the
effects of PGE2 on Th17 cell differentiation, indicating that672 Immunity 36, 668–679, April 20, 2012 ª2012 Elsevier Inc.IRF4 is necessary but not sufficient to mediate these effects
(Figure 5C). One possible implication of these results is that
beyond transcriptional repression of IRF4 itself, PGE2 also
induces other factors that prevent IRF4 DNA binding or tran-
scriptional activity. Indeed, PGE2 abolished IRF4 binding at
IL-17 and IL-22 promoter regions (Figure 5D). The inhibition of
binding was detectable 18 hr after PGE2 exposure, before
IRF4 protein started to decrease (Figure S4A). Because IRF4
promotes its own expression (Lehtonen et al., 2005), these
data suggest that PGE2 first prevents DNA binding by IRF4,
which then leads to decreased expression of IRF4 transcript
and protein.
The transcriptional repressor Bcl6 antagonizes IRF4 tran-
scriptional activity (Gupta et al., 1999) and is negatively regu-
lated by IRF4 in B cells (Saito et al., 2007), making it a candidate
mediator of IRF4 inhibition by PGE2. Overexpression of Bcl6 in
T cells suppresses Th17 cell development (Nurieva et al., 2009).
Consistent with negative regulation by IRF4 and an inhibitory
role on Th17 cell differentiation, Bcl6 protein and mRNA
expression increased with PGE2 treatment (Figure S4B). Loss
of Bcl6 had little effect on IL-17, IL-22, IRF4, or Rorgt expres-
sion, indicating that Bcl6 was not required for Th17 cell polar-
ization (Figure S4C). Bcl6 deficiency did not alter the inhibitory
effect of PGE2 on IL-17 but enhanced the ability of PGE2 to
augment IL-22 expression (Figure S4D), suggesting that Bcl6
inhibited IL-22 under these conditions and that induction of
Bcl6 may contribute to the paradoxical inhibition of IL-22 by
PGE2 when IRF4 is not present to counterbalance these
effects. Thus, PGE2 appears to exert its effects on multiple
transcription factors whose interplay during Th17 cell differen-
tiation remains to be fully understood, but these data taken
together suggest that inhibition of IRF4 is a central mechanism
by which PGE2 alters Th17 cell differentiation.
Cryptococcal PGE2 Suppresses IL-17 Production
from Naive T Cells
Cryptococcus neoformans, an opportunistic fungal pathogen
that is a leading cause of mortality in HIV-infected individuals
worldwide (Park et al., 2009), produces PGE2 via the enzyme
laccase (Erb-Downward et al., 2008). Laccase-deficient
Cryptococcus neoformans (Dlac1) strains are less virulent than
the wild-type H99 strain (Pukkila-Worley et al., 2005; Salas
et al., 1996). We speculated that inability of Dlac1 to produce
PGE2 (Zhu and Williamson, 2004) contributes to its decreased
virulence. To test our hypothesis that fungal PGE2 produc-
tion could directly alter T cell polarization, we differentiated
naive CD4+ T cells under Th17 cell polarization conditions
(anti-CD3+anti-CD28+IL-6+TGF-b) in the presence of either
wild-type H99 or Dlac1 mutant Cryptococcus. We found that
H99 inhibited T cell production of both IRF4 and IL-17, whereas
Dlac1 did not (Figures 6A and 6B). Neither H99 nor Dlac1 sup-
pressed IL-22 production, consistent with a specific inhibitory
effect on IL-17 production (Figure 6C). IRF4 inhibition by H99
was reversed by the addition of antagonists to the PGE2 recep-
tors EP2 or EP4 (Figure 6D). IL-17 inhibition by H99 was reversed
by the EP2 antagonist, but not by the EP4 antagonist (Figure 6E).
The inability of EP4 antagonism to recover IL-17 expression
despite the recovery of IRF4 expression may be due to inhibition
of IL-17 by enhanced FoxP3 expression under these conditions
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Figure 5. PGE2 Inhibits IRF4 Function
(A) Relative mRNA expression of FoxP3, IL-23R, IL-21,
and Rorgt 3 days after activation of wild-type or Irf4/
(‘‘KO’’ in figure) naive CD4+ T cells with TGF-b+IL-6 (top)
or wild-type cells with TGF-b+IL-6 in the absence or
presence of PGE2 (bottom).
(B) Relative expression of IL-17 and IL-22 after activation
of wild-type or Irf4/ naive CD4+ T cells in the presence
of TGF-b (1 ng/ml) and IL-6 plus PGE2 (0.1 or 1.0 mM).
(C) Retroviral overexpression of IRF4 (right) or vector (left)
in naive cells differentiated under Th17 cell conditions
with (bottom) or without (top) PGE2. Intracellular IL-22
and IL-17 were detected by flow cytometry in GFP+ cells.
(D) Relative chromatin binding of IRF4 in naive CD4+
T cells after Th17 cell-inducing conditions with (white
bars) or without (black bars) PGE2 displayed as percent
of input DNA after immunoprecipitation with IRF4 (left)
or isotype control (right) antibody. A CD11b coding
region is shown as a negative control for IRF4 binding.
IRF4 binding was assessed at three IL-17 promoter
regions and one IL-22 promoter region.
Data shown as mean ± SD. See also Figure S4.
Immunity
PGE2 Suppresses IRF4 and IL-17(data not shown) and suggests differential roles for EP2 and
EP4 receptors in regulating IL-17 expression. The ability of
PGE2 receptor antagonists to reverse IRF4 and IL-17 inhibition
is consistent with cryptococcal inhibition of IL-17 being driven
by PGE2 and not by other functions of laccase. These data
show that cryptococcal PGE2 can directly suppress IL-6-
mediated production of IL-17 by blocking the upregulation of
IRF4 required for IL-17 expression (Figure S5).Immunity 36,Indomethacin Increases IL-17
Production and Promotes Survival
after Cryptococcus Infection
Intranasal infection with Cryptococcus neofor-
mans in BALB/c mice leads to pulmonary
infection and mortality. We postulated that
PGE2 produced in the lungs by either the host
or fungus during infection might suppress
IL-17 production from developing T cells and
thus decrease immunity to the fungus. Deletion
of the laccase gene renders Cryptococcus less
virulent in mice; this may be due to loss of
fungal PGE2 production or due to loss of other
laccase functions. PGE2 can also be produced
in infected lung by host cells. Because it is
not feasible to specifically inhibit PGE2 syn-
thesis by cryptococcal laccase, we targeted
host PGE2 induction with the COX inhibitor
indomethacin. Treatment with indomethacin
beginning 1 day after Cryptococcus infection
reduced PGE2 metabolite concentrations in
the lung (Figure 7A). Indomethacin modestly
increased survival of infected mice by 3–
4 days (Figure 7B). This increased survival
required CD4+ T cells, as shown by the fact
that CD4+ T cell depletion before infection
caused mice to succumb at the same rate as
the control group (Figure 7C). Splenic CD4+
T cells isolated from infected mice treatedwith indomethacin produced more IL-17, but not IL-22, IFN-g,
or IL-4 (Figure 7D). In addition to CD4+ T cells, other cell types
including gd T cells, NK cells, and neutrophils have been re-
ported to produce IL-17. One week after infection, indometh-
acin-treated mice had an increased number of IL-17+ leukocytes
(CD45+) in bronchoalveolar lavage fluid (BALF) compared
to control mice (Figure 7E). Most of these were CD4+ T cells
and a smaller fraction were gd T cells (Figure 7E). Less than668–679, April 20, 2012 ª2012 Elsevier Inc. 673
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Figure 6. PGE2 Produced from Cryptococcus
Suppresses T Cell IRF4 and IL-17 Expression
(A–C) Naive CD4+ T cells were exposed to Th17 cell
differentiation conditions for 3 days in the presence of
wild-type H99 or Dlac1 Cryptococcus. The ratio of cryp-
tococci/T cells is indicated. T cells were then harvested to
determine relative mRNA expression of IRF4 (A), IL-17 (B),
and IL-22 (C).
(D and E) Naive CD4+ T cells activated as above in the
presence of H99 Cryptococcus were concomitantly
cultured with the EP2 antagonist AH6809 or the EP4
antagonist AH23848. Expression of IRF4 (D) and IL-17 (E)
mRNA is shown relative to TGF-b+IL-6 activation.
Data shown as mean ± SD. See also Figure S5.
Immunity
PGE2 Suppresses IRF4 and IL-170.1% of IL-17-producing cells in BALF were neutrophils with no
significant differences between the groups (data not shown).
Significant numbers of NK cells were not found. There was an
overall increase in IL-17+ cells in BALF 2 weeks postinfection,
but the effect of indomethacin was not sustained at this time
point (Figure 7F). Concordant with its effects on IL-17, indometh-
acin decreased lung cryptococcal burden 1 week after infection
but cryptococcal burden was equivalent to untreated mice by
2 weeks (Figure 7G). This early effect of indomethacin on IL-17
expression and cryptococcal burden contributed to the survival
advantage seen in treated mice as shown by the fact that this
was reversed with IL-17 blockade (Figure 7H). IL-17 blockade
or CD4 depletion had little effect on infected PBS-treated control
mice (Figures 7C and 7H), consistent with IL-17 already being
suppressed during infection, a likely contributing factor to the
recognized but incompletely understood susceptibility of this
mouse model to Cryptococcus. The observed effects of indo-
methacin treatment indicate that PGE2 blockade can augment
immunity to fungal infections by increasing early T cell IL-17
production.
DISCUSSION
Our data show that PGE2 acts during Th17 cell differentiation to
suppress IL-17 while enhancing IL-22 expression. Although674 Immunity 36, 668–679, April 20, 2012 ª2012 Elsevier Inc.IL-17 and IL-22 often appear to be coordinately
regulated in Th17 cells, the potential for dis-
cordant expression is evident with the identifi-
cation of ‘‘Th22’’ cells that express IL-22 but
not IL-17 (Duhen et al., 2009; Trifari et al.,
2009). Compared to the regulation of IL-17, the
regulation of IL-22 is poorly characterized. We
show that IRF4, a transcription factor critical
for IL-17 expression, suppresses IL-22 expres-
sion. By inhibiting IRF4, PGE2 simultaneously
enhances IL-22 and suppresses IL-17 expres-
sion. The influence of PGE2 on other tran-
scription factors, such as Bcl6, may contribute
to this effect. This differential activity of IRF4
is consistent with its known ability to act as
either a transcriptional activator or repressor at
different loci depending on cofactor binding
(Marecki and Fenton, 2002). A previous study
reported loss of IL-22 production in IRF4-deficient T cells in vitro but stable IL-22 production in vivo
(Bru¨stle et al., 2007). The sustained IL-22 production from
T cells in vivo is consistent with our results, and the in vitro
loss of IL-22 production may reflect different experimental
conditions that included use of TNF-a during polarization and
resting cells for 2 days before cytokine analysis.
IRF4 not only regulates Th17 cell differentiation but also
plays a crucial role in the differentiation of other T cell lineages
(Lohoff et al., 2002; Staudt et al., 2010; Zheng et al., 2009).
Of note, PGE2 has little effect on Th2 cells in vitro (Betz and
Fox, 1991), suggesting that the effects on IRF4 are specific
to IL-6-dependent Th17 cell differentiation. The mechanisms
responsible for this specificity remain to be determined. Because
IRF4 can interact with many different factors, such as PU.1,
FoxP3, and Bcl6, and because IRF4 can regulate itself, it is
possible that PGE2 targets an IRF4-associated factor that
regulates IRF4 specifically in the context of IL-6 effects.
PGE2 also appears to have disparate activities on T cells
depending on their differentiation status. In contrast to the
inhibition of IL-17 in naive T cells undergoing Th17 cell polariza-
tion, the addition of PGE2 to previously polarized Th17 cells
enhances IL-17 production. This difference may be due to
PGE2 targeting multiple pathways that play distinct roles at
these two stages. PGE2 inhibits IL-17 by suppressing IRF4
downstream of IL-6 receptor signaling, which is critical for
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Figure 7. PGE2 Blockade In Vivo Increases T Cell IL-17 Production and Prolongs Survival after Cryptococcus Infection
(A) PGE metabolites in BALF 13 days after infection with Cryptococcus and treatment with either PBS or indomethacin.
(B) Percent survival of mice infected with Cryptococcus and treated with either PBS or indomethacin (n = 10 mice per group).
(C) Percent survival with and without CD4 depletion of mice infected with Cryptococcus and treated with either PBS or indomethacin (n = 9–10 mice per group).
(D) IL-17, IL-22, IFN-g, and IL-4 from splenic CD4+ T cells isolated frommice 13 days postinfection (n = 5mice per group). Control mice (left bar) were not infected
and received no treatment.
(E and F) Number of IL-17-producing CD45+, CD4+, and gd+ cells in BALF from mice infected with Cryptococcus and treated with PBS or indomethacin
harvested 1 (E) or 2 (F) weeks postinfection.
(G) Colony forming units from whole lung 1 and 2 weeks after infection (n = 4 mice per group).
(H) Percent survival with and without IL-17 neutralization for mice infected with Cryptococcus and treated with either PBS or indomethacin (n = 8–10 mice
per group).
Data shown as mean ± SD.
Immunity
PGE2 Suppresses IRF4 and IL-17Th17 cell polarization. After polarization, signals other than IL-6,
such as IL-23, are important to promote IL-17 expression. PGE2
inhibited induction of IRF4 in response to IL-23 in polarized Th17
cells, but this did not inhibit IL-17 and IL-22 production. PGE2
can upregulate expression of IL-23R and IL-1R in mature
T cells (Boniface et al., 2009). This augmentation of IL-23 and
IL-1 pathways by PGE2 might explain the response of memory
Th17 cells to PGE2 that appears to be IRF4 independent.
Consistent with this divergent effect on IL-6 versus IL-23
pathways, cAMP-dependent enhancement of IL-17 productionis seen during IL-6-independent Th17 cell differentiation with
IL-1b and IL-23 (Datta et al., 2010). Understanding this differen-
tial regulation of T cell polarization under varying cytokine
contexts will be important to predict the effects of therapeutic
interventions such as PGE2 blockade with commonly used
nonsteroidal anti-inflammatory drugs (NSAIDs).
As mentioned previously, PGE2 can have different effects
depending on the context and cellular target of action. Its pleio-
tropic effects on innate immunity, adaptive immunity, and the
neuroendocrine axis make the net immune effect of systemicImmunity 36, 668–679, April 20, 2012 ª2012 Elsevier Inc. 675
Immunity
PGE2 Suppresses IRF4 and IL-17alterations in PGE2 difficult to predict. The ability of several
fungal pathogens to secrete their own PGE2 raises the intriguing
possibility that these pathogens may be able to use this pathway
to manipulate specific aspects of host immunity in the local
milieu during infection. We find that cryptococcal PGE2 can
directly affect T cell differentiation by suppressing IRF4
and thus IL-17 production. Inhibiting Th17 cell differentiation
locally during the early stages of infection may prevent the
development of optimal host defense.
Several studies have shown that protection from cryptococcal
infection correlates with IL-17 production. For instance, treat-
ment of mice with IL-23 enhanced IL-17 expression and
increased survival compared to IL-12 treatment (Kleinschek
et al., 2010). In addition, IL-17 expression is high in Il4/Il13/
mice after infection and this correlates with survival (Zhang et al.,
2009). In these models, IL-17 seems to play a role in controlling
early infection locally in the lung but the effects of IL-17 neutral-
ization during natural infection aremodest (Hardison et al., 2010),
consistent with preexistent suppression of IL-17 by cryptococcal
and host-derived PGE2. This suppressed IL-17 response prob-
ably contributes to the susceptibility of the mouse model to
Cryptococcus; our studies show that blockade of host PGE2
production during infection increases early IL-17 production by
CD4+ T cells that results in improved survival. This ability of
CD4+ T cell functional enhancement to increase mouse resis-
tance suggests that the susceptibility of the mouse model is at
least partially dependent on inadequate CD4+ T cell function,
mimicking the inadequate CD4+ T cell functionality and numbers
usually seen in humans who are susceptible to cryptococcal
disease. Of note, a similar benefit of PGE2 blockade in human
disease would require sufficient residual naive CD4+ T cell
numbers to mount an IL-17 response. Although our studies
show a clear role for CD4+ T cells, IL-17-producing gd T cells de-
tected in the lung may also contribute to the immune response
against Cryptococcus. The role of IL-22 and the potential
effect of its enhancement by PGE2 in fungal infections is less
clear, with evidence that it may contribute to immunity in some
contexts (Burbelo et al., 2010; Kisand et al., 2010; Puel et al.,
2010; Zelante et al., 2011) but not in others (Kagami et al., 2010).
Although inhibition of host PGE2 synthesis with indomethacin
lowered broncheoalveolar lavage PGE2 metabolite concentra-
tions, it is still possible that cryptococcal PGE2 accumulates
in microenvironments of the lung. Because Cryptococcus
uses COX-independent mechanisms to generate PGE2,
currently available pharmacologic COX inhibitors are ineffective
in inhibiting cryptococcal PGE2 synthesis. Developing specific
inhibitors of cryptococcal PGE2 synthesis to use alongside
COX inhibitors that block host PGE2 may be a strategy to
enhance the host antifungal response and optimize therapy
against this important fungal pathogen. Our work further sug-
gests that specific PGE2-mediated mechanisms (e.g., IRF4
inhibition) may be targeted to selectively modulate the pleio-
tropic effects of PGE2 on host immunity.EXPERIMENTAL PROCEDURES
Naive T Cell Isolation
Single-cell suspensions of spleens from 6- to 8-week-old C57BL/6 mice
were obtained with a GentleMACs tissue dissociator. After ACK lysis of red676 Immunity 36, 668–679, April 20, 2012 ª2012 Elsevier Inc.blood cells, CD4+ T cells were enriched by negative selection (Miltenyi Biotec).
Naive T cells (CD4+CD62L+CD44lo) were sorted on a FACSAria. Purity ranged
from 98% to 99%.
T Cell Activation
Anti-CD3ε (10 mg/ml) was coated overnight onto a 24-well plate. Naive T cells
were then cultured at 2 3 106 cell/ml/well in High Glucose DMEM with 10%
FCS (Hyclone), 2 mM Glutamax, 0.1 mM nonessential amino acids, 1 mM
sodium pyruvate, 55 mM beta-mercaptoethanol, 100 U/ml penicillin, and
100 mg/ml streptomycin (all from Invitrogen). Anti-CD28, anti-IL-4, and anti-
IFN-g were added to the wells with or without TGF-b, IL-6, IL-1b, IL-23, or
PGE2. When indicated, titrated numbers of Cryptococcus neoformans grown
overnight on starvation plates were added to the wells. After 3 days, cells
were harvested for RNA isolation or flow cytometry and supernatants were
harvested for ELISA. For restimulation, cells were replated at day 3 on
plates coated with anti-CD3 and soluble IL-23 or PGE2 for an additional
3 days. Reagent concentrations are detailed in Supplemental Experimental
Procedures.
Flow Cytometry
For intracellular staining, cells were activated for 4 hr with 50 ng/ml PMA and
1 mM ionomycin (Sigma-Aldrich). GolgiPlug (BD Biosciences) was added for
the final 3 hr. Cells were then stained with Aqua Live/Dead stain (Invitrogen),
fixed in 2% paraformaldehyde, and permeabilized in Cytoperm buffer (BD
Biosciences). FoxP3 staining buffers (eBioscience) were used for IRF4 and
Bcl6 staining. Cells were stained with PE-conjugated anti-IL-22 (clone
1H8PWSR, eBioscience), APC-conjugated anti-IL-17A (clone eBio17B7,
eBioscience), or FITC-conjugated anti-IFN-g (clone XMG1.2, eBioscience).
Data were acquired on a LSR II or LSR Fortessa flow cytometer (BD
Biosciences) and analyzed with Flowjo (Treestar). For sorting, cells were
enriched as described above and then stained with FITC-labeled anti-CD4
(clone RM4-5, eBioscience), PE-labeled anti-CD62L (clone MEL-14,
eBiosciences), and APC-labeled anti-CD44 (clone IM7, eBioscience). IRF4
was visualized with a PE-conjugated rat anti-mouse antibody (clone 3E4,
Santa Cruz Biotechnology). Anti-phospho-STAT3 (pY705) conjugated to Alexa
Fluor 488 was used per the manufacturer’s instructions (BD Biosciences).
PE-conjugated Bcl6 antibody was from eBioscience. For BALF analysis,
antibodies against the following antigens were used: CD45 (30-F11), CD4
(GK1.5), CD3 (17A2), gd (eBioGL3), CD49b (DX5), Gr-1 (RB6-8C5), CD11b
(M1/70), and IL-17 (eBio17B7) (all from eBioscience).
ELISA Assays
Phospho-STAT3 (pY705) was detected in T cell supernatants via the Pathscan
Inflammation Multi-Target Sandwich ELISA kit (Cell Signaling Technology).
The IL-17 ELISA set was from eBioscience and the IL-22 ELISA set was
from Antigenix. Multiplex cytokine detection in BALF was performed with the
Bio-Plex suspension array system (Bio-Rad).
Real-Time PCR
Real time data were obtained with Taqman One-Step RT-PCR Master Mix
reagents (Applied Biosystems). Samples were run in duplicate and normalized
to the housekeeping gene Actb. Data were reported according to the DDCt
method: DDCt = DCtsample  DCtreference. Primers are listed in Supplemental
Experimental Procedures.
STAT3 Immunoblot
Naive mouse CD4+ T cells (2 3 106) were cultured under IL-17-inducing
conditions with or without PGE2 (1.0 mM) for 0, 10, or 30 min. Cells were
stimulated with anti-CD3+anti-CD28 T activator Dynabeads (Invitrogen),
anti-IL-4 (10 mg/ml), anti-IFN-g (10 mg/ml), IL-6 (10 ng/ml), and human TGF-b
(1 ng/ml). Whole cell lysates weremade in RIPA buffer with Phenylmethanesul-
fonyl fluoride, Phosphatase Inhibitor Cocktail 2, and Protease Inhibitor
Cocktail (Sigma). For immunoblotting, protein was separated by SDS-PAGE,
transferred to nitrocellulose membranes by the iBlot Gel System (Invitrogen),
and probed with anti-pSTAT3 (D3A7 (Tyr705); Cell Signaling Technology),
anti-GAPDH (D15H11; Cell Signaling Technology), or anti-STAT3 (9132; Cell
Signaling Technology). IRDye 680LT donkey anti-rabbit antibody (LI-COR)
Immunity
PGE2 Suppresses IRF4 and IL-17was used for detection. Membranes were imaged with an Odyssey Infrared
Imaging System and Odyssey Classic Software (LI-COR).
siRNA Gene Targeting of IRF4
siRNA gene targeting of IRF4 expression was achieved with ON-TARGETplus
SMARTpool siRNA fromDharmacon. A nontargeting pool was used as a nega-
tive control. Naive T cells were stimulated (anti-CD3+anti-CD28+IL-6+TGF-b)
for 18 hr before nucleofection of siRNAs (Amaxa). Cytokines were then
replaced and cells were harvested 72 hr after the initiation of polarization.
Decreased IRF4 expression was confirmed by flow cytometry.
Chromatin Immunoprecipitation
Naive CD4+ T cells were activated overnight (18 hr) as described above with or
without 1 mMPGE2. Cells were fixed, nuclei lysed, and chromatin sheared with
a Misonex sonicator and cup horn. Immunoprecipitation was according to the
Millipore Magna-ChIP protocol. To precipitate IRF4 complexes, 2 mg of IRF4
polyclonal goat antibody was used (M-17, Santa Cruz Biotech). Goat IgG
was used as an isotype control. Percent input was determined by removing
an aliquot of sheared chromatin prior to immunoprecipitation and comparing
amplification of this DNA with amplification of the precipitated chromatin
with Sybr Green and real-time PCR (7500Fast, Applied Biosystems). IRF4-
binding sites in the IL-17 promoter regions were previously reported (Kwon
et al., 2009). Primers are listed in Supplemental Experimental Procedures.
Retroviral Transduction
Phoenix E cells were transfected with empty or IRF4-expressing retroviral
plasmids (pMSCV-IRES-GFP) via the calcium-phosphate method. After
48 hr viral supernatants were collected, filtered through a 0.45 mm filter, and
added to T cells (2 3 106) that had been cultured for 24 hr under Th17 cell
conditions with or without PGE2 (1 mM). The culture medium was replaced
with 1 ml of viral supernatant and Polybrene (10 mg/ml, Millipore), and cells
were centrifuged for 1 hr at 1,000 3 g and 30C. Cells were then incubated
for 1 hr at 37C before replacement of viral supernatant with prewarmed
culture medium supplemented with respective cytokines at half the initial
concentration. Cells were analyzed by flow cytometry 48 hr later.
Mouse Infection Studies
Cryptococcus neoformans strain H99 was grown for 2 days on YPD agar
plates. On the day of infection, cells were scraped off the plates, resuspended
in PBS, and counted. Mice were anesthetized with isoflurane and 1 3 106
Cryptococcus cells in 20 ml PBS was administered via the nostril. Beginning
1 day after infection, mice were injected intraperitoneally with 100 mg of indo-
methacin or vehicle in PBS every other day. For in vitro T cell studies, spleens
were isolated after 13 days. Colony forming units (CFU) were obtained by
homogenizing whole lungs at 1 and 2 weeks postinfection. For depletion
of CD4+ cells, 1 mg of CD4 antibody (GK1.5, BioXCell) or isotype control
(LTF-2, BioXCell) was injected intraperitoneally 1 day prior to infection. Flow
cytometry 1week later confirmed 99.9%depletion of CD4+ T cells in the blood.
For blockade of IL-17, mice were injected with 100 mg of IL-17 antibody (17F3,
BioXCell) or isotype control (MOPC-21, BioXCell) every other day starting on
the day of infection. BALF was obtained by lavage of the lungs with 1 ml
cold PBS. All animal experiments were done in compliance with the guidelines
of the NIAID Institutional Animal Care and Use Committee.
PGE2 Metabolite Assay
PGE2 metabolite concentration in BALF was determined in duplicate samples
with Prostaglandin E Metabolite EIA Kit (Cayman).
Statistical Analysis
Statistics were calculated with the unpaired Student’s t test (two-tailed) with
Prism software (GraphPad). *p < 0.05, **p < .001, and ***p < 0.001.
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